Back to mobile site

More on RNAZ

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/17/25 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

TransCode Therapeutics (NQ:RNAZ)
Delayed: 5.09 -0.51 (9.11%)
Prev. Close $5.60  
Open$5.43 
52 Wk High$ 
52 Wk Low$ 
Day High$5.68 
Day Low$4.50 
P/E N/A  
EPS$ 
Volume83,317 


Jun 8, 2026 08:04 AM TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Jun 3, 2026 08:09 AM Form 8-K Transcode Therapeutics, For: Jun 03
Jun 3, 2026 08:04 AM TransCode completes phase 1a cancer trial with no dose-limiting toxicities
Jun 3, 2026 08:04 AM TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
Jun 2, 2026 04:18 PM Form ARS Transcode Therapeutics, For: Dec 31
Jun 2, 2026 04:06 PM Form DEF 14A Transcode Therapeutics, For: Jul 02
Jun 1, 2026 09:00 AM Form 8-K Transcode Therapeutics, For: May 29
May 27, 2026 08:04 AM TransCode starts phase 2a trial for colorectal cancer drug
May 27, 2026 08:04 AM TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
May 26, 2026 06:46 AM Form DEFA14A Transcode Therapeutics,
View All Articles

Entities mentioned with RNAZ

View All Entities